As reviewed by Ferreira et al.,54 at least the ‘older’ GLP‐1 receptor agonists liraglutide and exenatide showed numerical trends in HFrEF patients towards higher hospitalization rates in the FIGHT (liraglutide) and EXSCEL (exenatide) trials, more arrhythmias (FIGHT and LIVE trials for liraglutide), or even all‐cause death (FIGHT trial). Here, GLP1R is linked to cardiac arrhythmia.